Lidocaine infusion sits at the center of this dementia and brain health question.
Lidocaine infusion is an intravenous pain treatment that delivers the common numbing agent directly into the bloodstream, where it acts on the central nervous system to reduce chronic pain signals. Originally known as a local anesthetic for dental work and minor procedures, lidocaine administered through an IV has shown meaningful analgesic, anti-inflammatory, and anti-hyperalgesic properties that extend well beyond the injection site. A 2025 study on subcutaneous lidocaine infusion for chronic widespread pain found 61% average pain relief lasting approximately 19 days per infusion, numbers that have caught the attention of pain specialists searching for alternatives to long-term opioid prescriptions.
The treatment is not new, but it is gaining fresh momentum. Amid the ongoing opioid crisis, clinicians and patients alike are looking for non-opioid options that can meaningfully reduce suffering without the addiction risks that come with narcotics. IV lidocaine is used off-label for this purpose, meaning it lacks specific FDA approval for chronic pain, but a growing body of clinical research is pushing the conversation forward. This article covers how the infusion works, what conditions it treats, the clinical evidence behind it, its limitations and costs, and what the latest 2025 research means for people living with persistent pain, particularly older adults and those with cognitive decline who may be unable to clearly communicate their discomfort.
Table of Contents
- How Does IV Lidocaine Infusion Work for Pain Relief?
- What Conditions Can Lidocaine Infusion Treat, and Where Does It Fall Short?
- What Does the Latest 2025 Research Say About Lidocaine for Chronic Pain?
- What Does a Lidocaine Infusion Cost, and Will Insurance Pay for It?
- Risks, Side Effects, and Who Should Avoid Lidocaine Infusion
- Lidocaine Infusion in the Context of Dementia-Related Pain
- Where Is Lidocaine Infusion Research Headed?
- Conclusion
- Frequently Asked Questions
How Does IV Lidocaine Infusion Work for Pain Relief?
Lidocaine belongs to the amide class of local anesthetics, but when it enters the bloodstream through an IV line, its behavior changes significantly compared to a simple numbing injection. Systemically, lidocaine blocks voltage-gated sodium, potassium, and calcium channels throughout the body. It also acts on NMDA receptors in the central nervous system, which play a key role in chronic pain sensitization. This multi-target mechanism is part of what makes it appealing. Unlike a drug that hits a single receptor, lidocaine interrupts pain signaling through several pathways simultaneously, which may explain why some patients with treatment-resistant conditions experience relief when other medications have failed. In clinical settings, dosages range from 1 mg/kg to 7.5 mg/kg, with infusion durations spanning from 30 minutes to 6 hours depending on the protocol and the condition being treated.
At UCSF, inpatients receive IV lidocaine for up to 48 hours under qualified pain service management. A more moderate protocol used by some pain clinics involves 1,000 mg total over 25 hours at a rate of 40 mg/hour. A prospective case series published in 2022 from a UK pain clinic documented infusions typically lasting 1 to 2 hours. The variation in protocols reflects the fact that there is no single standardized approach, which is both a strength in terms of flexibility and a limitation when it comes to comparing outcomes across studies. For context, contrast this with a nerve block, which numbs a specific region for hours, or an opioid, which dampens pain perception globally but carries tolerance and dependence risks. IV lidocaine sits somewhere between these approaches. It offers systemic relief without the sedation or addiction potential of opioids, but its effects are temporary, and the treatment requires medical monitoring throughout.
What Conditions Can Lidocaine Infusion Treat, and Where Does It Fall Short?
The list of conditions treated with IV lidocaine is broad. It includes neuropathic pain such as diabetic neuropathy and postherpetic neuralgia, fibromyalgia, complex regional pain syndrome, chronic low back pain, cancer pain, and postoperative pain, where it has been shown to reduce opioid consumption after abdominal surgery. Acute conditions like renal colic, critical limb ischemia, and acute migraine have also been treated with the infusion. For people with dementia or cognitive impairment who may experience chronic pain but struggle to articulate it, the potential for a non-sedating pain treatment that does not cloud cognition further is particularly relevant. However, the evidence is uneven across these conditions, and enthusiasm must be tempered with honesty.
Multiple randomized controlled trials for postherpetic neuralgia, CRPS, and diabetic neuropathy have failed to show durable long-term effects. Relief appears mostly short-term, lasting hours to weeks rather than months. The UK’s National Institute for Health and Care Excellence advises that IV local anesthetics should not be offered for primary chronic pain outside of clinical trials. This is not a blanket dismissal of the treatment, but it signals that the evidence has not yet reached the threshold that major health authorities require for routine recommendation. If you or a family member is considering lidocaine infusion for a condition like fibromyalgia or neuropathic pain, it is worth asking the treating physician which specific studies support its use for that diagnosis and what realistic outcomes look like. A treatment that offers three weeks of 50% pain reduction may be transformative for some patients and inadequate for others, depending on the severity of the condition and available alternatives.
What Does the Latest 2025 Research Say About Lidocaine for Chronic Pain?
Two studies published in 2025 have added significant detail to the lidocaine conversation. The first, published in PLOS One, examined IV lidocaine infusion specifically for fibromyalgia. Researchers defined responders as patients who experienced at least 50% pain reduction lasting a minimum of three weeks after receiving lidocaine at 5 mg/kg. The study identified a pattern among responders: they tended to be female, younger, with a shorter duration of generalized pain and lower baseline weekly pain scores. This finding matters because it moves toward something the pain field desperately needs, the ability to predict who will benefit before starting treatment rather than relying on trial and error.
The second study, published in the MDPI Journal of Clinical Medicine, explored subcutaneous lidocaine infusion rather than IV delivery for chronic widespread pain. This approach found 61% average pain relief lasting approximately 19 days per infusion. Subcutaneous delivery is potentially more practical than IV infusion because it may not require the same level of hospital-based monitoring, opening the door to outpatient or even home-based treatment in the future. For older adults or people with dementia who find hospital visits disorienting and stressful, a simplified delivery method could remove a significant barrier to accessing this kind of pain management. Together, these studies represent a shift from asking whether lidocaine works toward asking for whom it works best and how it can be delivered most effectively. Predictive biomarker research, like the fibromyalgia study’s identification of responder characteristics, could eventually allow clinicians to personalize pain treatment in a way that reduces wasted time, unnecessary procedures, and patient frustration.
What Does a Lidocaine Infusion Cost, and Will Insurance Pay for It?
The drug itself is surprisingly inexpensive. A 50 mL vial of 2% preservative-free lidocaine costs approximately $68.87 at retail. But the total cost of an infusion session extends well beyond the medication. Facility fees, cardiac monitoring, nursing supervision, physician oversight, and geographic location all factor into the final bill, and these can vary widely between a hospital-based pain clinic and a freestanding outpatient center. The larger financial challenge is insurance coverage. Blue Cross Blue Shield of Massachusetts and Rhode Island, for example, considers IV lidocaine infusion for chronic pain, including neuropathic pain, chronic daily headache, and fibromyalgia, to be investigational. This classification means coverage is frequently denied.
Most major insurers have adopted similar positions, leaving patients to pay out of pocket. Some clinics offer payment plans, and the relatively low cost of the drug itself means the financial barrier is more about the procedure and monitoring than the medication. Still, for someone who needs repeated infusions every few weeks to maintain relief, costs accumulate quickly. Compare this to the cost landscape of other chronic pain treatments. Long-term opioid prescriptions carry their own medical costs plus the societal burden of addiction treatment. Spinal cord stimulators can cost $30,000 to $50,000 for implantation. Lidocaine infusion falls somewhere in the middle, less expensive than surgical interventions but potentially more costly than medication management alone when insurance will not contribute. Patients should ask their provider about prior authorization, appeals processes, and whether any clinical trial participation might provide access at reduced cost.
Risks, Side Effects, and Who Should Avoid Lidocaine Infusion
Lidocaine infusion is generally well tolerated at therapeutic doses, but it is not without risk. Common side effects include dizziness, numbness or tingling around the mouth, and a metallic taste. These effects are typically dose-dependent and resolve as the infusion rate is lowered or the infusion ends. More serious risks emerge at higher doses or in patients with certain cardiac conditions. Cardiac arrhythmia and seizures are the most concerning potential complications, which is why infusions require continuous cardiac monitoring and should only be administered by qualified medical personnel with resuscitation equipment available. For older adults, particularly those with dementia, the risk profile warrants extra caution.
Many people with cognitive decline also have cardiovascular disease, kidney impairment, or liver dysfunction, all of which can affect lidocaine metabolism and increase the likelihood of toxicity. The liver processes lidocaine, so reduced hepatic function, which is common in aging, means the drug may stay in the system longer and at higher concentrations than expected. A clinician experienced with lidocaine infusion should adjust dosing based on weight, organ function, and concurrent medications. Drugs that inhibit certain liver enzymes can elevate lidocaine levels unpredictably. There is also the question of cognitive side effects. While lidocaine does not carry the sedation or confusion risks of opioids, dizziness and altered sensation during infusion may be distressing for someone who already experiences confusion or disorientation. Caregivers should be present during and after the procedure, and the treating team should be informed of any dementia diagnosis so they can monitor for behavioral changes that the patient may not be able to report.
Lidocaine Infusion in the Context of Dementia-Related Pain
Pain in dementia is one of the most underrecognized problems in elder care. People with moderate to advanced cognitive decline often cannot describe their pain in words, leading to undertreatment or misattribution of pain behaviors to the dementia itself. A person who becomes agitated, resists care, or withdraws socially may be in significant pain that is going unaddressed. Lidocaine infusion offers an interesting possibility in this context because it does not produce the sedation, constipation, or cognitive dulling associated with opioids, side effects that are particularly harmful in people whose cognitive reserves are already diminished.
That said, the practical challenges are real. Infusions require IV access, monitoring, and a clinical setting, all of which can be difficult to arrange for someone with advanced dementia who may not understand what is happening. The subcutaneous delivery method explored in the 2025 MDPI study could eventually make this more feasible. If future research confirms that subcutaneous lidocaine provides comparable relief with less intensive monitoring, it could become a genuinely useful tool for managing chronic pain in cognitively impaired populations where opioid alternatives are urgently needed.
Where Is Lidocaine Infusion Research Headed?
The direction of current research suggests that lidocaine infusion is moving from a niche, last-resort treatment toward a more targeted therapy with defined patient selection criteria. The 2025 fibromyalgia study’s work on identifying responder characteristics, such as being female, younger, with shorter pain duration and lower baseline pain scores, represents early steps toward biomarker-driven patient selection. If clinicians can predict with reasonable accuracy who will respond before administering the infusion, the treatment becomes more efficient, more cost-effective, and easier to justify to insurers.
The exploration of subcutaneous delivery is equally important. IV infusions are resource-intensive, requiring trained staff, monitoring equipment, and clinical space. A subcutaneous alternative that patients could potentially receive in less intensive settings, or even at home with appropriate training, would dramatically expand access. Combined with the broader push for non-opioid pain management strategies, lidocaine infusion appears poised to become a more prominent part of the chronic pain treatment landscape over the next several years, though it will need stronger long-term efficacy data and standardized protocols before it can move from investigational to routine.
Conclusion
Lidocaine infusion represents a genuinely promising non-opioid approach to chronic pain management, with particular relevance for conditions like neuropathic pain, fibromyalgia, and complex regional pain syndrome. The 2025 research into subcutaneous delivery and responder prediction marks a meaningful step forward, and the treatment’s favorable side effect profile compared to opioids makes it worth serious consideration, especially for older adults and people with cognitive decline who are disproportionately harmed by sedating pain medications. The evidence for 61% average pain relief lasting nearly three weeks is encouraging, if not yet sufficient to overcome the investigational classification that limits insurance coverage. For patients and caregivers exploring this option, the practical next steps are straightforward.
Ask a pain management specialist whether lidocaine infusion is appropriate for the specific diagnosis in question. Request information about the clinic’s protocol, including dosage, duration, and monitoring practices. Clarify costs upfront and check with your insurer about coverage or appeal options. And approach the treatment with realistic expectations: lidocaine infusion may provide meaningful short-term relief and reduce the need for opioids, but it is not a cure for chronic pain, and repeated sessions will likely be necessary to maintain its benefits.
Frequently Asked Questions
Is lidocaine infusion FDA-approved for chronic pain?
No. IV lidocaine for chronic pain is used off-label. While lidocaine itself is FDA-approved as a local anesthetic, its intravenous use for conditions like fibromyalgia, neuropathic pain, and CRPS does not have specific FDA approval.
How long does pain relief last after a single lidocaine infusion?
Relief varies significantly by condition and individual. Research on subcutaneous lidocaine for chronic widespread pain found an average of 19 days of relief per infusion. Some patients experience only hours of benefit, while others report weeks. Multiple randomized trials have noted that long-term durable effects remain unproven.
Will my insurance cover lidocaine infusion for pain?
Most major insurers, including Blue Cross Blue Shield, currently classify IV lidocaine infusion for chronic pain as investigational or experimental, which means coverage is frequently denied. Patients often pay out of pocket, though some clinics offer payment plans.
Is lidocaine infusion safe for elderly patients or people with dementia?
It can be administered to older adults, but extra caution is needed. Reduced liver and kidney function, common in aging, can slow lidocaine metabolism and increase toxicity risk. Cardiac monitoring is essential, and caregivers should be present to help communicate any side effects the patient may not be able to report.
What are the most common side effects of lidocaine infusion?
Common side effects include dizziness, numbness or tingling around the mouth, and a metallic taste. These are usually mild and dose-dependent. Serious but rare risks include cardiac arrhythmia and seizures, which is why continuous monitoring is required during infusion.
How does lidocaine infusion compare to opioids for chronic pain?
Lidocaine infusion does not carry the addiction, tolerance, sedation, or cognitive impairment risks associated with opioids. It has opioid-sparing properties, meaning it can reduce the amount of opioid medication a patient needs. However, its pain relief tends to be shorter-lasting and requires clinical visits for administration, whereas opioids can be taken at home.
You Might Also Like
- Ketamine Infusion for CRPS: The Treatment That Works When Nothing Else Does
- Lynch Syndrome and Immunotherapy: Why Genetics Change Treatment
- Why Doctors Are Alarmed by This Supplement Influencers Are Pushing
For more, see NIH MedlinePlus — cognitive testing.
